All articles in Treatment innovations

Sleep Apnea – Pipeline Review, H2 2014 – Radiant Insights, Inc J

Originally posted in Medgadget on JULY 24TH, 2015 RADIANT INSIGHTS, INC.


Global Markets Direct’s, ‘Sleep Apnea – Pipeline Review, H2 2014′, provides an overview of the Sleep Apnea’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sleep Apnea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Sleep Apnea and special features on late-stage and discontinued projects.

To Get More Details @

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Read More

Sound waves can improve sleep and memory, study says



Sound wave therapy can improve sleep and memory, according to a new study fromNorthwestern Medicine in the US.

According to Psych Central, Neuroscience graduate student Nelly Papalambros wanted to find out if there was a non-invasive way to improve sleep quality, because of its many effects on health. Poor sleep has been linked to everything from cognitive problems (including memory issues and difficulty concentrating) to heart attack and disease, while insomnia drastically increases the risk of accident and injury.

Papalambros recruited study participants with an increased risk of heart disease, and measured their baseline stats and sleep patterns while they stayed at a sleep research centre overnight. She then tested whether playing a low-grade static noise could improve their quality of sleep. This sound was developed by Giovanni Santostasi and is personalised in order to be more effective.

Read More

ImThera Medical gets US FDA nod for pivotal study for obstructive sleep apnea device

Originally posted in San Diego, California
Wednesday, November 12, 2014, 14:00 Hrs  [IST]

ImThera Medical, a privately held global medical device company, announced that the US Food and Drug Administration (US FDA) has approved an investigational device exemption (IDE) for its THN3 Clinical Study. The THN3 Study will evaluate the safety and effectiveness of the aura6000 System for moderate to severe obstructive sleep apnea (OSA) in individuals who are unable to comply or unwilling to try PAP therapy or other OSA treatments. Data from this pivotal clinical study will be used to support a Pre-Market Approval (PMA) application for the aura6000 System.

“This is the most exciting innovation for the treatment of sleep apnea since CPAP,” said Michael Friedman, M.D., Professor of Otolaryngology and director of Chicago Sleep Center at Rush University Medical Center, Chicago IL and a study investigator. “I have had experience implanting the device during the earlier THN2 study.

Read More

SomnoMed Limited receives U.S. approval for sleep apnea devices

24th Jun 2014, 6:57 pm by Proactive Investors

SomnoMed Limited receives U.S. approval for sleep apnea devices

SomnoMed Limited (ASX:SOM) has received FDA 510(k) approval from the U.S. Department of Health & Human Services for its sleep apnea devices, allowing it to start sales in July.

The approvals were received for its new SomnoDent® Fusion Classic and SomnoDent® Fusion Flex oral appliances that were introduced at conventions at the beginning of June.

These have exchangeable wings, which makes adjustments of the forward position of the SomnoDent® device easier for the practitioner and patient.

Both products offer improvements over existing sleep apnea devices and a greater level of patient comfort.

The company’s products are already distributed throughout 16 countries in Europe, which represents 40% of its global sales.

Outlook for European sales volume and revenue growth in FY14/15 is strong.

Originally posted in Proactiveinvestors.

Read More

Pin It on Pinterest